BioSpace News Archive

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”) today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.

Susan G. Komen®, the world’s leading breast cancer organization, announced four new global leaders to serve on its Board of Directors.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA.

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to announce that allowance has been granted for the Composition of Matter of its PharmAla-1 (P-1) molecule by the US Patent and Trademark Office (USPTO).

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced a pivotal peer-reviewed publication entitled, “Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients with Synucleinopathies”1 in the Journal of the American Medical Association (JAMA).

Levita Magnetics today announced a significant breakthrough in surgical technology through its deployment of augmented reality (AR) in abdominal surgeries.

Boston Imaging, the United States headquarters of Samsung’s digital radiography and ultrasound business, was awarded HHM Health’s Healthcare Innovator Award for its SonoSync technology and contributions to closing the gap in quality, accessible healthcare for underserved communities.

Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.

Corealis Pharma Inc. is pleased to announce that the expansion project of its state-of-the-art laboratory facilities is completed ahead of schedule and is on track to be fully operational by the end of the second quarter of 2024.